Latest Strategic Development News

Flagship Minerals’ metallurgical review of the Pantanillo Gold Project highlights strong gold recoveries from oxide mineralisation and suggests a pathway to low capital and operating costs through heap and dump leach processing.

Metal Bank Limited reported a net cash outflow in Q1 2025, with limited cash runway prompting strategic funding considerations including potential project sales.

SIV Capital Limited reported a modest positive net cash flow for Q3 FY25 and holds over $8 million in cash, yet its ASX securities remain suspended pending compliance with listing rules.

3P Learning reports a modest revenue decline but nearly doubles its underlying EBITDA in the first half of FY25, signaling operational improvements amid a transitional phase.

AUCyber Limited reported a substantial $19.5 million net loss for the half-year ended December 2024, driven by a $14.7 million impairment following underperformance post-merger. The company has since received and recommended a takeover bid from 5G Networks Limited.

Macarthur Minerals Limited reported a comprehensive loss of AUD 252,771 for Q4 2024, marking a sharp reversal from the prior year's profit. The company is navigating reduced exploration spending and strategic asset sales while facing ongoing funding challenges.

Delta Lithium has revealed significant progress in its Western Australian lithium and gold assets, underpinned by robust resource estimates and ongoing exploration. The company’s strategic focus on capital discipline and monetising gold positions it well for future growth.

Equinox Resources' Managing Director Zac Komur presented a detailed update on the Alturas Antimony Project, highlighting exceptional exploration results and strategic progress in British Columbia.

AGL Energy’s half-year results reveal a 15.3% revenue increase to $7.13 billion, but statutory profit plunges 83.2% to $97 million, reflecting margin pressures and significant provisions. The company declares a lower fully franked interim dividend of 23 cents per share.

SomnoMed Limited prepares to unveil its H1FY25 financial results on February 28, 2025, accompanied by a live investor presentation and Q&A session. The company remains a global leader in sleep apnea treatment solutions.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

JB Hi-Fi Limited reported a robust half-year performance for the period ending December 31, 2024, with revenue up 9.9% and net profit rising 8.1%, underpinned by strong segment contributions and a strategic acquisition. The company declared a healthy interim dividend of 170 cents per share, signalling confidence in its financial position.